Telix expects FY 2026 revenue, other income above US$1 billion, tracks upper end of guidance

Telix Pharmaceuticals Limited Sponsored ADR

Telix Pharmaceuticals Limited Sponsored ADR

TLX

0.00
  • Telix forecast FY 2026 revenue and other income above US$1 billion.
  • Revenue outlook tracking near the upper end of US$950 million to US$970 million, supported by a US$40 million non-refundable Regeneron payment.
  • Q2 group revenue reached US$247 million, up 7% QoQ, up 21% YoY; Precision Medicine revenue was US$202 million, up 9% QoQ.
  • FY 2026 R&D spend guidance lifted to US$230 million to US$270 million, enabled by commercial performance and the Regeneron payment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607201931PRIMZONEFULLFEED9765216) on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.